Anixa Biosciences (ANIX)
(Delayed Data from NSDQ)
$3.15 USD
-0.11 (-3.37%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $3.18 +0.03 (0.95%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ANIX 3.15 -0.11(-3.37%)
Will ANIX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANIX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANIX
Is Anixa Biosciences (ANIX) Stock Outpacing Its Medical Peers This Year?
Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?
ANIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
ANIXA BIOSCIENCES INC (ANIX) is a Great Momentum Stock: Should You Buy?
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
What Makes ANIXA BIOSCIENCES INC (ANIX) a Strong Momentum Stock: Buy Now?
Other News for ANIX
ANIX: D. Boral Capital Reaffirms 'Buy' Rating with $10 Price Target | ANIX Stock News
Insider Buying: Titterton Lewis H jr Acquires Additional Shares of Anixa Biosciences Inc (ANIX)
Anixa Biosciences (ANIX) Advances Breast Cancer Vaccine to Phase 2 Trials
Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming ...
Anixa plans to begin Phase 2 of breast cancer vaccine trial